COMPANY PROFILE

Stramsen Biotech

Houston-based biopharmaceutical company developing innovative therapics for the treatment of infectious and noninfectious diseases

Houston, United StatesFounded 2020Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Stramsen Biotech

Stramsen Biotech Inc., headquartered in Houston, Texas, is a biopharmaceutical company specializing in the development of plant-based medicines. The company focuses on creating treatments for both infectious and noninfectious diseases, leveraging a vast database of over 8,000 medicinal plants. Stramsen Biotech's product line includes SBX 1052, which targets prostate gland enlargement, and SBX 1968 and SBX 2021, which aim to control the proliferation and metastasis of prostate and various cancer cells, respectively. The company serves a global market, addressing the needs of patients requiring alternative medicinal solutions. Stramsen Biotech operates on a business model that emphasizes rigorous clinical trials to ensure the efficacy and safety of its products. Revenue is generated through the development and commercialization of these plant-based medicines. The company is committed to scientific inquiry, from initial research concepts to experimental execution and result analysis. Key personnel include Dr. Sabina, the Chief Medical Officer and Clinical Trials Specialist, who brings expertise from her medical and healthcare administration background. Stramsen Biotech is currently seeking funding to advance clinical trials and expand its research capabilities.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Houston, United States
Employees: 5
Open positions: None listed
Dealroom signal: 49.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GROWTH EQUITY VC✓Equity / VC	Apr 2025	$25M	—	Global Emerging Markets	↗
EARLY VC✓Equity / VC	Oct 2023	$20M	$807M	Undisclosed	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Stramsen Biotech website traffic

Latest recorded traffic for Stramsen Biotech is 740 monthly website visits, up 1.4% over the last three months. Stramsen Biotech's team declined 16.7% over the past year.

Latest monthly visits740 3-month web change+1.4% 1-year team growth-16.7%

Monthly website visitsOct 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SSSecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform	Minneapolis, United States	Operational	19	$17M	$28M
FUFunPepFunPep is an Industry-university collaboration bioventure company	Ibaraki, Japan	Operational
AIArterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors	Atlanta, United States	Operational
LYLysoclearPremium laboratory research services for biotechnology and pharmaceutical companies, specializing in ocular toxicology and structural biology	Lafayette, United States	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ANAmygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction	Palo Alto, United States	Operational
ATAnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products	Huangpu, China	Acquired
CBContraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics	Siena, Italy	Operational